Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia
b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced results from its Phase 2 study of LYN-005, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) risperidone capsule, in development for the weekly treatment of schizophrenia.
- b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced results from its Phase 2 study of LYN-005, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) risperidone capsule, in development for the weekly treatment of schizophrenia.
- The study included a lead-in period in which patients received IR risperidone tablets (2 mg or 4 mg) for 13 days in order to achieve a steady therapeutic state.
- It affects approximately 2.2 million U.S. adults, often beginning in the late teens or early twenties.
- For more information, visit the Company\xe2\x80\x99s website at www.lyndra.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210418005010/en/\n'